Gulf International Bank UK Ltd Sells 5,679 Shares of Hologic, Inc. $HOLX

Key Points

• Gulf International Bank UK Ltd reduced its holdings in Hologic, Inc. by 29.5% in Q1, selling 5,679 shares, which left them with a total of 13,544 shares valued at approximately $836,000.
• Hologic's recent quarterly earnings surpassed analysts' expectations, reporting $1.08 earnings per share and revenue of $1.02 billion, marking a 1.2% increase year-over-year.
• Analysts have positive outlooks for Hologic, with upgrades from several firms, including Royal Bank Of Canada's price target increase from $72.00 to $87.00, indicating growing confidence in the company's performance.

Gulf International Bank UK Ltd decreased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 29.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,544 shares of the medical equipment provider's stock after selling 5,679 shares during the period. Gulf International Bank UK Ltd's holdings in Hologic were worth $836,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HOLX. Victory Capital Management Inc. boosted its stake in Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after purchasing an additional 1,692,177 shares during the period. Nuance Investments LLC lifted its holdings in shares of Hologic by 623.7% in the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock worth $66,794,000 after buying an additional 931,920 shares in the last quarter. Redwood Wealth Management Group LLC purchased a new position in shares of Hologic in the first quarter worth $3,534,000. Invesco Ltd. boosted its position in shares of Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after acquiring an additional 764,573 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Hologic by 26.9% during the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after acquiring an additional 668,086 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of research analyst reports. Evercore ISI boosted their target price on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Raymond James Financial reaffirmed an "outperform" rating and issued a $71.00 price objective (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and raised their target price for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. Finally, Argus upgraded shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 price target on the stock in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Trading Up 1.4%

Shares of HOLX traded up $0.94 during mid-day trading on Wednesday, reaching $68.76. 1,890,938 shares of the company's stock traded hands, compared to its average volume of 2,791,663. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The stock's 50-day moving average is $65.71 and its two-hundred day moving average is $62.50. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The stock has a market cap of $15.29 billion, a P/E ratio of 28.53, a P/E/G ratio of 2.44 and a beta of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic's revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.